A one-fifth dose of Bavarian Nordic’s mpox vaccine Jynneos can elicit a similar antibody response as its standard-dose regimen, according to findings presented Saturday at the European Society of ...
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a ...
Bavarian Nordic A/S, a fully integrated vaccine company, announced that Jynneos, the only FDA-approved mpox vaccine, is now commercially available in the US, marking a significant expansion for access ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
This 2003 electron microscope image made available by the Centers for Disease Control and Prevention shows a monkeypox virion, obtained from a sample associated with the 2003 prairie dog outbreak.
COPENHAGEN, Denmark, April 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons ...
COPENHAGEN, Denmark, April 2, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a ...
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a ...